Partnering
Our modular approach to ADC design enables partnering flexibility, with strategic collaborations tailored to deliver maximum value for patients and partners.
Through innovative platforms that work independently or in combination, we address multiple hallmarks of cancer, providing partners with powerful tools to tackle difficult-to-treat tumors.
Our end-to-end capabilities, spanning pre-clinical and clinical R&D, in-house GMP manufacturing, and regulatory engagement, enable efficient development from discovery through to commercial launch. We are open to exploring a range of approaches, including strategic collaborations, licensing opportunities, co-development partnerships and new company formation, across our platforms and proprietary programs.
EU and FDA Inspected & Approved Manufacturing Facilities
Our team of approximately 200 highly qualified employees work in our state-of-the art research and development and GMP manufacturing and conjugation facilities for both mAbs and ADCs in Nijmegen, the Netherlands. Our activities span across 73,000 square meters, combining leading expertise in precision oncology drug development with proven GMP delivery capabilities.
Contact us by filling in the form below or send an email to BD@Byondis.com
Personal data contained in this form is intended for the sole use of Byondis.
We will use this data to respond to your question or obtain additional information from you as needed.
Please see the Byondis Privacy and cookie statement.
Platforms
Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, advanced masking technologies, and linker and drug conjugation strategies.
Press Releases
Stay up to date with the latest news from Byondis, including company milestones, clinical progress, and partnership announcements. Our press releases reflect our commitment to advancing innovative targeted medicines for people living with cancer.
